Cas no 366017-09-6 (Mubritinib)

Mubritinib is a small-molecule inhibitor targeting the tyrosine kinase domain of HER2 (human epidermal growth factor receptor 2), exhibiting potent activity against HER2-overexpressing cancer cells. It functions by selectively binding to the ATP-binding site of HER2, thereby inhibiting downstream signaling pathways critical for cell proliferation and survival. Preclinical studies have demonstrated its efficacy in suppressing tumor growth in HER2-positive breast and gastric cancers. Mubritinib also shows favorable pharmacokinetic properties, including oral bioavailability and manageable toxicity profiles. Its specificity for HER2, combined with its ability to overcome certain resistance mechanisms, positions it as a promising candidate for targeted cancer therapy. Further research is ongoing to explore its full therapeutic potential.

Mubritinib structure

Product Name:Mubritinib

CAS No:366017-09-6

MF:C₂₅H₂₃F₃N₄O₂

MW:468.470936059952

MDL:MFCD09954135

CID:67862

PubChem ID:354335238

Update Time:2025-05-27

Mubritinib Chemical and Physical Properties

Names and Identifiers

- Mubritinib
- 1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole
- Mubritinib (TAK 165)
- 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole
- Mubritinib TAK 165
- TAK 165
- TAK-165
- (E)-1-(4-(4-((2-(4-(trifluoromethyl)styryl)oxazol-4-yl)methoxy)phenyl)butyl)-1H-1,2,3-triazole
- Mubritinib,TAK 165,TAK165
- UNII-V734AZP9BR
- (E)-4-((4-(4-(1H-1,2,3-triazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole
- 1-[4-[4-[[2-[(1E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-1,2,3-triazole
- CID 6444692
- (E)-4-[[4-[4-(1H-1,2,3-Triazol-1-yl)butyl]phenoxy]methyl]-2-[4-(trifluoromethyl)styryl]oxazole
- TAK165
- V734AZP9BR
- C25H23F3N4O2
- 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]eth
- SMR004458708
- EX-A2107
- Mubritinib (USAN/INN)
- NCGC00346582-08
- 1-(4-(4-((2-((E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)oxazol-4-yl)methoxy)phenyl)butyl)-1H-1,2,3-triazole
- [4-[4-[[2-[(E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole
- GTPL6011
- CHEMBL1614707
- 1-[4-[4-[[2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]triazole
- Mubritinib;TAK-165
- HMS3414A21
- NS00070519
- (E)-4-((4-(4-(1H-1,2,3-triazol-1-yl)butyl)phenyl1H-1,2,3-triazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole
- 1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole
- BDBM50593765
- MUBRITINIB [INN]
- SW219659-1
- Mubritinib [USAN:INN]
- s2216
- BCP9000012
- 1-[4-[4-[[2-[(E)-2-(4-trifluoromethylphenyl)ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]-butyl]-1H-1,2,3-triazole
- MUBRITINIB, FREE BASE
- CCG-269433
- DB12682
- HY-13501
- HMS3678A21
- 1-[4-[4-[[2-[(E)-2-(4-trifluoromethylphenyl)ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole
- 366017-09-6
- Mubritinib [USAN]
- SCHEMBL94943
- MLS006010161
- AC-5248
- 1-[4-[4-[[2-[(E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]oxazol-4-yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole
- NSC-800802
- 1-[4-[4-[[2-[(E)-2-[-4-(trifiuoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole
- NSC800802
- AKOS015918001
- CS-3954
- Q6930896
- Mubritinib, >=98% (HPLC)
- BCP02837
- 1-[4-[4-[[2-[(E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole
- DTXSID501026014
- Mubritinib; TAK-165
- AS-16256
- 1H-1,2,3-triazole, 1-(4-(4-((2-((1E)-2-(4-(trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-
- D04025
- MFCD09954135
- A823310
- LS-15096
- M3058
- BRD-K19061412-001-02-4
- BRD-K19061412-001-03-2
- SDCCGSBI-0654404.P001
- BRD-K19061412-001-04-0
- Mubritinib (TAK 165)?
- MDL： MFCD09954135
- Inchi： 1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+
- InChI Key： ZTFBIUXIQYRUNT-MDWZMJQESA-N
- SMILES： FC(C1C=CC(=CC=1)/C=C/C1=NC(=CO1)COC1C=CC(=CC=1)CCCCN1C=CN=N1)(F)F

Computed Properties

Exact Mass: 468.17700
Monoisotopic Mass: 468.177311
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 0
Hydrogen Bond Acceptor Count: 8
Heavy Atom Count: 34
Rotatable Bond Count: 10
Complexity: 620
Covalently-Bonded Unit Count: 1
Defined Atom Stereocenter Count: 0
Undefined Atom Stereocenter Count : 0
Defined Bond Stereocenter Count: 1
Undefined Bond Stereocenter Count: 0
Topological Polar Surface Area: 66
XLogP3: 5.4

Experimental Properties

Density: 1.25
Melting Point: 158.0 to 162.0 deg-C
Boiling Point: 620.9°C at 760 mmHg
Flash Point: 329.3°C
Refractive Index: 1.577
PSA: 65.97000
LogP: 6.05720

Mubritinib Security Information

Signal Word：Warning
Hazard Statement： H302-H315-H320-H335
Warning Statement： P261-P280-P301+P312-P302+P352-P305+P351+P338
Hazardous Material transportation number：NONH for all modes of transport
Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month

Mubritinib Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	M129797-250mg	Mubritinib	366017-09-6	≥99%	250mg	￥6179.90	2023-09-02
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	M129797-50mg	Mubritinib	366017-09-6	≥99%	50mg	￥1628.90	2023-09-02
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	M129797-10mg	Mubritinib	366017-09-6	≥99%	10mg	￥415.90	2023-09-02
S e l l e c k ZHONG GUO	S2216-10mM (1mL in DMSO)	Mubritinib (TAK 165)	366017-09-6	99.94%	10mM (1mL in DMSO)	￥736.09	2023-09-16
S e l l e c k ZHONG GUO	S2216-10mg	Mubritinib (TAK 165)	366017-09-6	99.94%	10mg	￥581.24	2023-09-16
S e l l e c k ZHONG GUO	S2216-25mg	Mubritinib (TAK 165)	366017-09-6	99.80%	25mg	￥1218.18	2022-04-26
S e l l e c k ZHONG GUO	S2216-200mg	Mubritinib (TAK 165)	366017-09-6	99.94%	200mg	￥7127.59	2023-09-16
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.	R024143-10mg	Mubritinib (TAK 165),99%	366017-09-6	99%	10mg	￥499	2024-05-24
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.	R024143-250mg	Mubritinib (TAK 165),99%	366017-09-6	99%	250mg	￥7416	2024-05-24
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.	R024143-50mg	Mubritinib (TAK 165),99%	366017-09-6	99%	50mg	￥1955	2024-05-24

Mubritinib Suppliers

Amadis Chemical Company Limited

Gold Member

Audited Supplier

(CAS:366017-09-6)Mubritinib

Order Number:A823310

Stock Status:in Stock

Quantity:50mg/100mg

Purity:99%

Pricing Information Last Updated:Friday, 30 August 2024 05:17

Price ($):166.0/314.0

Email:[email protected]

Product Official Link

Mubritinib Related Literature

1. Isoxazole derivatives of 6-fluoro-N-(6-methoxybenzo[d]thiazol-2-yl)benzo[d]thiazol-2-amine and N-(pyrimidin-2-yl)benzo[d]thiazol-2-amine: regulation of cell cycle and apoptosis by p53 activation via mitochondrial-dependent pathways

Ravindra M. Kumbhare,Tulshiram L. Dadmal,T. Anjana Devi,Dinesh Kumar,Umesh B. Kosurkar,Debabrata Chowdhury,K. Appalanaidu,Y. Khageswara Rao,M. Janaki Ramaiah,Manika Pal Bhadra Med. Chem. Commun. 2014 5 1744
2. Synthesis, study of antileishmanial and antitrypanosomal activity of imidazo pyridine fused triazole analogues

Adinarayana Nandikolla,Singireddi Srinivasarao,Banoth Karan Kumar,Sankaranarayanan Murugesan,Himanshu Aggarwal,Louise L. Major,Terry K. Smith,Kondapalli Venkata Gowri Chandra Sekhar RSC Adv. 2020 10 38328
3. Synthesis and antiproliferative activity of 1H-1,2,3-triazole-4H-chromene-d-glucose hybrid compounds with dual inhibitory activity against EGFR/VEGFR-2 and molecular docking studies

Dinh Thanh Nguyen,Son Hai Do,Thi Huyen Le,Thi Hanh Nguyen,Minh Huyen Nguyen,Thi Ngoc Bich Vu,Thi Thu Hien Pham,Ngoc Toan Vu,Thi Kim Van Hoàng,Thi Kim Giang Nguyen New J. Chem. 2022 46 23179
4. Synthesis and biological evaluation of triazole and isoxazole-tagged benzothiazole/benzoxazole derivatives as potent cytotoxic agents

Tulshiram L. Dadmal,K. Appalanaidu,Ravindra M. Kumbhare,Tanmoy Mondal,M. Janaki Ramaiah,Manika Pal Bhadra New J. Chem. 2018 42 15546
5. Facile synthesis of 1,5-disubstituted 1,2,3-triazoles by the regiospecific alkylation of a ruthenium triazolato complex

Chao-Wan Chang,Gene-Hsiang Lee Dalton Trans. 2019 48 2028

Related Categories

366017-09-6 (Mubritinib) Related Products

Recommended suppliers